Annexon, Inc. is a biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases affecting nearly 10 million people worldwide. Its pipeline includes tanruprubart (anti-C1q antibody for Guillain-Barré Syndrome), vonaprument (intravitreal C1q inhibitor for geographic atrophy/dry AMD), ANX1502 (oral small molecule C1s inhibitor for autoimmune conditions), and ANX009 (subcutaneous C1q-blocking Fab for lupus nephritis). The company targets the classical complement pathway by blocking C1q, the initiating molecule, across autoimmune, neurodegeneration, and ophthalmology therapeutic areas.
expected 2026-11-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-131782 | EDGAR | 83K words |
| 2025-03-03 | 2024-12-31 | 0000950170-25-030849 | EDGAR | 82K words |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036408 | EDGAR | 93K words |
| 2023-03-06 | 2022-12-31 | 0000950170-23-006232 | EDGAR | 82K words |
| 2022-03-01 | 2021-12-31 | 0001564590-22-008044 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015262 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-346779 | EDGAR | 57K words |
| 2025-11-10 | 2025-09-30 | 0001193125-25-274240 | EDGAR | 57K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108869 | EDGAR | 56K words |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069200 | EDGAR | 53K words |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127057 | EDGAR | 55K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095401 | EDGAR | 54K words |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058659 | EDGAR | 52K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062913 | EDGAR | 53K words |
| 2023-08-07 | 2023-06-30 | 0000950170-23-039054 | EDGAR | 52K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018797 | EDGAR | 51K words |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021509 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015560 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001193125-26-345672 | EDGAR | 3K words |
| 2026-08-10 | 0001193125-26-342524 | EDGAR | 1K words |
| 2026-08-06 | 0001193125-26-336867 | EDGAR | 2K words |
| 2026-07-30 | 0001193125-26-326199 | EDGAR | 1K words |
| 2026-03-30 | 0001193125-26-131746 | EDGAR | 3K words |
| 2026-02-17 | 0001193125-26-054695 | EDGAR | 1K words |
| 2026-01-14 | 0001193125-26-012918 | EDGAR | 3K words |
| 2026-01-12 | 0001193125-26-009740 | EDGAR | 2K words |
| 2025-11-14 | 0001193125-25-283191 | EDGAR | 1K words |
| 2025-11-10 | 0001193125-25-274220 | EDGAR | 3K words |
114 total filings indexed. 86 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001528115 |
| Ticker | ANNX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.annexonbio.com |
| Listed | 2020-07-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ANNX (~200 tokens, structured JSON with cryptographic provenance)